Norma Pence

Michigan regulators are asking for volunteers to provide input for the state’s  new recreational marijuana industry rules , and the cannabis industry is responding to ensure its views are heard. The state is forming work groups to cover four regulatory topics: Existing medical marijuana license holders interested in entering the adult-use market. Municipalities that are considering allowing licensed recreational facilities in their community. Attorneys who represent marijuana establishments that have an interest in the adult-use market. Individuals or businesses interested in participating in the market as potential licensees or consumers. Morgan Fox, spokesman for the National Cannabis Industry Association (NCIA), noted that its Michigan members will be actively involved in the effort, as will its allied association, the Michigan Cannabis Industry Association. Fox said the NCIA also is planning to make its resources, such as best practices and industry standards, available

Currently, there are two different types of plants that are used in the extraction and manufacturing process of cannabidiol , popularly known as CBD . These plants both belong to the cannabis genus and are marijuana and hemp. Both plants are then further cultivated into a range of different strains that contain especially high concentrations of certain cannabinoids. Since CBD is CBD regardless of the plant from which it is sourced, do you really need to concern yourself with the type of plant the manufacturer uses? Does  hemp CBD oil for sale online  vary from other CBD oil that might come from marijuana or that doesn’t specify a specific source crop? There are a few different reasons why it may not matter and other reasons why it matters a great deal. Why It Shouldn’t Matter In a perfect world, it wouldn’t really matter whether CBD was derived from hemp or marijuana because CBD is a common chemical compound in both plants. There’s nothing that differentiates CBD derived from m

Efforts to create a taxed and regulated marijuana market in Vermont advanced Thursday after the state Senate approved a bill to allow legal cannabis sales. The legislation was approved by a roll call vote of 23 to 5—a veto-proof margin. After an additional procedural vote in the Senate, likely on Friday, the proposal will head to the House of Representatives. If enacted into law, S. 54 would establish the Cannabis Control Board as the state’s regulatory body for a legal marijuana market. Five types of licenses for various cannabis businesses would be available, and cannabis sales would be taxed with an excise tax of 16 percent, plus a two percent local option tax. The bill also includes measures to encourage women and communities disproportionately impacted by prohibition and the war on drugs to join the newly legal market. “Today’s strong, tri-partisan vote sends a clear message that Vermonters of all political stripes are ready to regulate commercial cultivation and sale of alrea

Efforts to create a taxed and regulated marijuana market in Vermont advanced Thursday after the state Senate approved a bill to allow legal cannabis sales. The legislation was approved by a roll call vote of 23 to 5—a veto-proof margin. After an additional procedural vote in the Senate, likely on Friday, the proposal will head to the House of Representatives. If enacted into law, S. 54 would establish the Cannabis Control Board as the state’s regulatory body for a legal marijuana market. Five types of licenses for various cannabis businesses would be available, and cannabis sales would be taxed with an excise tax of 16 percent, plus a two percent local option tax. The bill also includes measures to encourage women and communities disproportionately impacted by prohibition and the war on drugs to join the newly legal market. “Today’s strong, tri-partisan vote sends a clear message that Vermonters of all political stripes are ready to regulate commercial cultivation and sale of alrea

Cannabis stocks were mostly higher Thursday, as investors digested the latest earnings reports from the sector and comments from the head of the U.S. Food and Drug Administration on plans for regulation of CBD. FDA Commissioner Scott Gottlieb said public meetings will be held sometime in April to hear from relevant parties on how best to regulate CBD derived from hemp, which was legalized in December in the 2018 Farm Bill. The FDA is now responsible for regulating CBD, a non-psychoactive ingredient in cannabis that was not included in hemp legalization because of a lack of research into its longer-term effects on human health. CBD is widely held to have wellness properties and many cannabis companies are planning to launch food, drinks and cosmetics that contain it, but the FDA has said they cannot do so without its prior approval. Gottlieb told a hearing before a House Appropriations subcommittee that the FDA will form a working group of experts to inform him on regulatory options

Sen. Cory Booker (D-NJ) and several of his rivals for the 2020 Democratic presidential nomination are joining forces on Thursday to re-file a new version of the most far-reaching marijuana legislation ever introduced in Congress. TODAY: I’m reintroducing the Marijuana Justice Act – my bill to legalize marijuana on the federal level, expunge records, and reinvest in the communities that have been hurt from the war on drugs. pic.twitter.com/LWL0j7fN5F — Sen. Cory Booker (@SenBooker) February 28, 2019 The bill, the Marijuana Justice Act, would remove cannabis from the Controlled Substances Act and withhold certain federal funding from states that disproportionately enforce marijuana criminalization laws against people of color and low-income individuals. Watch Booker and colleagues discuss the legislation below: The legislation would also automatically expunge past federal convictions for cannabis use and possession, as well as create a fund to reinvest in communities hardest hit b

Sen. Cory Booker (D-NJ) and several of his rivals for the 2020 Democratic presidential nomination are joining forces on Thursday to re-file a new version of the most far-reaching marijuana legislation ever introduced in Congress. TODAY: I’m reintroducing the Marijuana Justice Act – my bill to legalize marijuana on the federal level, expunge records, and reinvest in the communities that have been hurt from the war on drugs. pic.twitter.com/LWL0j7fN5F — Sen. Cory Booker (@SenBooker) February 28, 2019 The bill, the Marijuana Justice Act, would remove cannabis from the Controlled Substances Act and withhold certain federal funding from states that disproportionately enforce marijuana criminalization laws against people of color and low-income individuals. Watch Booker and colleagues discuss the legislation below: The legislation would also automatically expunge past federal convictions for cannabis use and possession, as well as create a fund to reinvest in communities hardest hit b

Original Article Source: https://www.livescience.com/64886-thc-cbd-marijuana-therapeutic-effects.html

Food and Drug Administration (FDA) Commissioner Scott Gottlieb revealed new details about plans to pursue alternative pathways for CBD regulation and also acknowledged that federal prohibition drives research into medical marijuana overseas on Wednesday. Gottlieb’s latest comments were in response to questions from Reps. Barbara Lee (D-CA), Chellie Pingree (D-ME) and Mark Pocan (D-WI) during a hearing before a House Appropriations subcommittee. Among the revelations that came out of the hearing was that Gottlieb will shortly announce that the FDA will hold a public meeting “sometime in April” to hear from stakeholders about how to best regulate CBD derived from hemp, which was legalized late last year as part of the 2018 Farm Bill . He also said he’d be forming a working group comprised of agency experts to inform him on regulatory options for CBD. Pocan wanted to know “how actively” the FDA was considering different pathways to regulate food and dietary supplements that contain he

This weekly series from Marijuana Business Daily and Viridian Capital Advisors provides the latest data on cannabis investment activity and M&A, along with key takeaways, analysis and trends based on recent market moves. The data below, provided by Viridian Capital Advisors, is through the week ended Feb. 22. Capital raise highlights: Innovative Industrial Properties (NYSE: IIPR ), a cannabis industry-focused real estate investment trust, closed a $144 million raise – capital it plans to use to purchase properties to lease back to marijuana operators. “As more investors come in that don’t want to touch the plant, they could be more open to this type of real estate investment opportunity,” said Harrison Phillips, vice president with Viridian Capital Advisors. Boston-based Ascend Wellness Holdings, a multistate vertically integrated marijuana operator, closed a $55 million funding round – capital the firm will use to expand in its home state of Massachusetts and other market

Food and Drug Administration (FDA) Commissioner Scott Gottlieb revealed new details about plans to pursue alternative pathways for CBD regulation and also acknowledged that federal prohibition drives research into medical marijuana overseas on Wednesday. Gottlieb’s latest comments were in response to questions from Reps. Barbara Lee (D-CA), Chellie Pingree (D-ME) and Mark Pocan (D-WI) during a hearing before a House Appropriations subcommittee. Among the revelations that came out of the hearing was that Gottlieb will shortly announce that the FDA will hold a public meeting “sometime in April” to hear from stakeholders about how to best regulate CBD derived from hemp, which was legalized late last year as part of the 2018 Farm Bill . He also said he’d be forming a working group comprised of agency experts to inform him on regulatory options for CBD. Pocan wanted to know “how actively” the FDA was considering different pathways to regulate food and dietary supplements that contain he

Food and Drug Administration (FDA) Commissioner Scott Gottlieb revealed new details about plans to pursue alternative pathways for CBD regulation and also acknowledged that federal prohibition drives research into medical marijuana overseas on Wednesday. Gottlieb’s latest comments were in response to questions from Reps. Barbara Lee (D-CA), Chellie Pingree (D-ME) and Mark Pocan (D-WI) during a hearing before a House Appropriations subcommittee. Among the revelations that came out of the hearing was that Gottlieb will shortly announce that the FDA will hold a public meeting “sometime in April” to hear from stakeholders about how to best regulate CBD derived from hemp, which was legalized late last year as part of the 2018 Farm Bill . He also said he’d be forming a working group comprised of agency experts to inform him on regulatory options for CBD. Pocan wanted to know “how actively” the FDA was considering different pathways to regulate food and dietary supplements that contain he